Research Interest: He focused on developing novel adjuvants and vaccine delivery systems for prophylactic vaccination along with rational design of new vaccine formulations for Novartis discovery projects.

Research Interest: Cytokine based Immunotherapies to treat lymphopenia, Clinical biomarkers in psychological disorders, Effects of Inflammation on hematopoiesis.

Research Interest: Pathogenesis and Treatment of Melanoma, and in Part are directed at Developing Tools to Study Melanoma.

Research Interest: Public Health and Health Technology Assessment, particularly for vaccines. 

Research Interest: Diagnosis of fungal infections; Therapy of mycoses; Pathogenesis of fungal infection; Antifungal drug resistance; Fungal infection animal model; Genomics in medical mycology; Candida mucosal immunity; Infectious dermatosis; genodermatoses.

Research Interest: Currently, his studies focus on the two major directions. The first one is to study the innate receptor TLR and NLR ligands as adjuvant for CTL epitope-based vaccines to treat cancer and the adjuvant effect on the modulation of immune responses will be studied.

Research Interest: Genitourinary Cancer

Since July 2008, assistant in the Department of Epidemiology, MU- Plovdiv

From April 2020 epidemiologist at the Hygiene and Epidemiology Department, University Hospital "St. George" EAD

From September 2022 Acting Head of the Hygiene and Epidemiological Department, University Hospital "St. George" EAD

On 27.12.2020 applied the first vaccine in the history of the vaccination campaign against COVID-19 in Plovdiv

In 2021, she was part of the Ministry of Education and Culture of the Republic of Bulgaria campaign to educate teachers about vaccines against COVID-19.

In 2021-2022 advises on vaccines againstCOVID-19 on the National Patient Helpline toll-free Organization.

2021-2022 cooperates with the foundation "For our children"

2021-2023 participated in expert meetings on epidemiology at the Ministry of Health of the Republic of Bulgaria.

In 2022,  she was part of a working group at the Council of Ministers- Republic of Bulgaria.

Member of:

International epidemiological association (IEA) Bacti Vac Network. Bulgarian Scientific Society for Epidemiology of Infectious and Non-Infectious Diseases Bulgarian Association of Preventive Medicine. The South Bulgarian Society of Infectious Diseases, Epidemiology and Parasitology. Bulgarian Association for Prevention and Infection Control.

Research Interests:

Vaccines, vaccinology, infectious diseases, emerging diseases, epidemics, pandemics, COVID-19, varicella, shingles, measles.

List of Publications:

1. Tomov L, Chervenkov L, Miteva DG, Batselova H, Velikova T. Applications of time series analysis in epidemiology: Literature review and our experience during COVID-19 pandemic. World J Clin Cases. 2023 Oct 16;11(29):6974-6983. doi: 10.12998/wjcc.v11.i29.6974. PMID: 37946767; PMCID: PMC10631421.
   
2. Mileva N, Vasilev GH, Ganev B, Chervenkov L, Batselova H, Tzotcheva I, Tomov L, Velikova T, Lazova S. Cardiovascular Manifestations of Multisystem Inflammatory Syndrome in Children: A Single-Center Bulgarian Study. Medicina (Kaunas). 2023 Dec 14;59(12):2175. doi: 10.3390/medicina59122175. PMID: 38138278; PMCID: PMC10744581.
3. Dimitrov, G., Valkov, T., Batselova, H., Kounchev, O., Momekov, G., Argirova, R. Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020-April 2022 (2023) BMJ Open, 13 (8), art. no. e068431,
4. Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G.V., Tomov, L., Velikova, T. The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice (2023) Vaccines, 11 (7), art. no. 1181.
5. Ivanov N, Krastev B, Miteva DG, Batselova H, Alexandrova R, Velikova T. Effectiveness and safety of COVID-19 vaccines in patients with oncological diseases: State-of-the-art. World J Clin Oncol. 2023 Sep 24;14(9):343-356
6. Tomov, L., Batselova, H., Lazova, S., Ganev, B., Tzocheva, I., Velikova, T. Role of children in the Bulgarian COVID-19 epidemic: A mathematical model study (2023) World Journal of Experimental Medicine, 13 (3), pp. 28-46.
7.  Sekulovski, M. Mileva, N. Vasilev, G.V. Miteva, D. Gulinac, M. Peshevska-Sekulovska, M. Chervenkov, L. Batselova, H. Vasilev, G.H.; Tomov, L.; et al. Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination. Biomedicines 2023, 11, 2813.
8. Slabakova, Y.; Gerasoudis, S.; Miteva, D.; Peshevska-Sekulovska, M.; Batselova, H.; Snegarova, V.; Vasilev, G.V.; Vasilev, G.H.; Sekulovski, M.; Lazova, S.; et al. SARS-CoV-2 Variant-Specific Gastrointestinal Symptoms of COVID-19: 2023 Update. Gastroenterol. Insights 2023, 14, 431-445. https://doi.org/10.3390/gastroent14040032 .
9. Tomov, L.P., Batselova, H., Velikova, T.Changes in Patterns of Infectivity and Mortality with SARS-CoV-2 Omicron Variant in Bulgaria.Computer Science and Education in Computer Science. CSECS 2023. Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, vol 514. Springer, Cham. https://doi.org/10.1007/978-3-031-44668-9_15.
10. Tomov, L.P., Batselova, H.M., Velikova, T.V. COVID-19 Delta Wave Caused Early Overburden of Hospital Capacity in the Bulgarian Healthcare System in 2021 (2022) Healthcare (Switzerland), 10 (4), art. no. 600.
11. Tomov, L., Batselova, H., Velikova, T.V. Estimating COVID Case Fatality Rate in Bulgaria for 2020–2021(2022) Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, LNICST, 450 LNICST, pp. 102-115.
12. Snegarova V, Miteva D, Gulinac M, Peshevska-Sekulovska M, Batselova H, Velikova T. COVID-19 inpatients with gastrointestinal stromal tumors: Recommendations for management and vaccination. World J Gastrointest Pathophysiol 2022; 13(5): 170-177
13. Vasilev G, Kabakchieva P, Miteva D, Batselova H, Velikova T. Effectiveness and safety of COVID-19vaccines in patients with diabetes as a factor for vaccine hesitancy. World J Diabetes 2022; 13(9): 738-751.
14. Miteva D, Peshevska-Sekulovska M, Snegarova V, Batselova H, Alexandrova R, Velikova T. Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J Virol 2022; 11(5): 221-236.
15. Tomov L, Miteva D, Sekulovski M, Batselova H, Velikova T. Pandemic control-do's and don'ts from a control theory perspective. World Journal of Methodology 12.5 (2022): 392.
16. Velikova, T., Kukov, A., Mihova, A., Snegarova, V., Batselova, H., Nakov, R. Gastrointestinal mucosal immunity and covid-19 (2021) World Journal of Gastroenterology, 27 (30), pp. 5047-5059.
17. Tomov, L., Velikova, T., Batselova, H. HEALTH RISK MANAGEMENT IN KINDERGARTENS AND SCHOOLS DURING COVID-19 PANDEMIC (2021) General Medicine, 23 (6), pp. 22-27.
    
18. Velikova, T., Batselova, H., Jenkov, V. IMPACT OF COVID‐19 PANDEMIC ON MENTAL HEALTH: A CROSS‐SECTIONAL SURVEY OF 1,020 BULGARIAN CITIZENS. Bulgarian Journal of Psychiatry (2020), 5 (3) , 10-18.
19. Velikova TV, Kotsev SV, Georgiev DS, Batselova HM. Immunological aspects of COVID-19: What do we know? World J Biol Chem. 2020 Sep 27;11(2):14-29.
20. Бацелова Х., Кеворкян А., Райчева Р., Бойкинова О., Балтаджиев И., Шопова Й., Стоилова Й. Епидемиологично проучване на хоспитализираните пациенти с варицела в Пловдивска област за периода 2000-2011г. Обща медицина, 2013, XV (3).
21. Baltadzhiev, I., Stoilova, J., Popivanova, N., Bazelova, H. Changes in the Viral Hepatitis B (VHB) morbidity 1987-2006 (2009) Problems of Infectious and Parasitic Diseases, 37 (1), pp. 39-40. 

Research Interest: Antigen processing and presentation, relating to the understanding of these processes and manipulation of them in order to treat.

Research Interest: Virology/Microbiology, Biochemistry, Clinical Diagnostics, Molecular Biology, Protein Chemistry.

David A. Reardon, MD, is a Professor of Medicine at Harvard Medical School and currently serves as Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute.

He previously served as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for eleven years. He completed his residency at John Hopkins Hospital in Maryland, USA and was awarded a fellowship at the University of Michigan. Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors.

His work includes using innovative clinical therapeutic agents to improve outcome for patients with brain and spinal tumors, with particular focus on immunotherapeutics. He has also led investigations of molecular-targeting agents, anti-angiogenic reagents, cytotoxins and other biologically-based therapies.

Dr. Reardon has published over 290 peer-reviewed manuscripts. He received the R. Wayne Rundles Award for Excellence in Cancer Research as well as the Award for Excellence in Adult Clinical Research by the Society for Neuro-Oncology in 2015 and 2016. He also served as the tenth president of the Society for Neuro-Oncology from 2013-2015.

Research Interest: Innovative Clinical Therapeutic Agents To Improve Cure Rates In Patients With Brain And Spinal Tumors, With Particular Focus On Immunotherapeutics As Well As Molecular-Targeting Agents, Anti-Angiogenic Reagents, Cytotoxins And Other Biologically-Based Therapies.

Research Interest: Veterinary Vaccine and Immunology, Veterinay Virology (Canine distemper virus, Canine parvovorus and Classical swine fever virus.

Research Interest: Pediatric Immunology: Primary Immunodeficiencies (particularly their autoimmune manifestations), Early-onset Autoimmunity, Human Thymus, Mother-Infant Immunological Relationships (focusing Placental and Milk Antibody Transfer).

Research Interest: Cancer immunology, vaccines, cancer, antigen-presenting cells and viral immunology.

Research Interest: Infectious disease, vaccine, immunology, focus in infectious diseases, epidemiology, microbiology, vaccine development and efficacy.